http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 03 Aug 2026 16:09:13 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Press+Releases/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html <ul class="bwlistdisc"> <li> <b>U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)</b> </li> <li> <b>Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications</b> </li> <li> <b>Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market</b> </li> </ul> <p> BAD HOMBURG, Germany--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 </p><p> Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize http://www.streetinsider.com/Business+Wire/Fresenius+Announces+FDA+Approval+of+Rituximab+Biosimilar+for+the+U.S.+Market/26857850.html Mon, 03 Aug 2026 16:09:00 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344